Annual General Meeting Presentation 2017

November 17, 2017 Kerry Rowe

AGM Presentation 2017

Post navigation

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Annual General Meeting Presentation 2017

Related Posts

Prana’s Parkinson’s drug meets Michael J. Fox Foundation development milestone – PBT434 advances through IND enabling studies

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

Prana Provides Clinical Trials Update: Alzheimer’s and Huntington disease trials on track